To evaluate the efficacy of catheter ablation combined with anticoagulation therapy in reducing recurrent stroke and major cardiovascular outcomes in patients with atrial fibrillation and recent ischemic stroke, specifically comparing it to standard therapy.
Key Findings:
No significant reduction in primary composite outcome of recurrent ischemic stroke, systemic embolism, all-cause death, or hospitalization for heart failure between groups (p-value needed).
Event rates were comparable: 4.9 per 100 person-years in standard therapy vs 5.6 in ablation group (HR: 1.11).
Recurrent ischemic stroke rates were similar: 3.1 vs 2.5 events per 100 person-years (p-value needed).
Interpretation:
The study did not demonstrate a clear clinical benefit of catheter ablation in reducing stroke risk in this patient population, possibly due to lower-than-expected event rates and treatment crossover, which may reflect advances in atrial fibrillation management.
Limitations:
Lower-than-anticipated event rates reduced statistical power, making it difficult to detect differences.
Treatment crossover affected results, with 14% of participants switching groups.
Conducted exclusively in Japan, limiting generalizability to other populations.
Conclusion:
The addition of catheter ablation to anticoagulation therapy did not provide significant benefits in preventing recurrent strokes or major cardiovascular events in patients with atrial fibrillation post-stroke, reinforcing the need for further research.
